Antoinette R Tan

16PUBLICATIONS
92CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsTumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (16)

|Sep 11, 2026
Evaluation of a Tumor-Informed Molecular Residual Disease Assay in Early Triple-Negative Breast Cancer Treated With Neoadjuvant Chemotherapy, With or Without Atezolizumab.

|Mar 11, 2026
ToPCourT protocol: a phase II trial of Trilaciclib, Pembrolizumab, gemcitabine, and Carboplatin in locally advanced/unresectable or metastatic Triple-negative breast cancer.

Megan B Sears-Smith, Ashley Matusz-Fisher, James T Symanowski

|Jan 31, 2025
Human Epidermal Growth Factor Receptor 2 Alterations and Prognostic Implications in All Subtypes of Breast Cancers.

Arielle L Heeke, Andrew Elliott, Kaitlyn O'Keefe

|Dec 05, 2024
Genomic Landscape of Malignant Phyllodes Tumors Identifies Subsets for Targeted Therapy.

Rani Bansal, Tolulope Adeyelu, Andrew Elliott

|Oct 15, 2024
Trastuzumab Deruxtecan with Nivolumab in HER2-Expressing Metastatic Breast or Urothelial Cancer: Analysis of the Phase Ib DS8201-A-U105 Study.

Erika Hamilton, Matthew D Galsky, Sebastian Ochsenreither

|Sep 03, 2024
Practical Guidance on Abemaciclib in Combination with Adjuvant Endocrine Therapy for Treating Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative High-Risk Early Breast Cancer.

Kaitlyn O'Keefe, Neelam V Desai, Antoinette R Tan

Pageof 3

Frequent Collaborators

2 joint publications

George W Sledge

2 joint publications

Arielle L Heeke

2 joint publications

Joyce O'Shaughnessy

2 joint publications

James T Symanowski